Gilead Voluntary Recalls One Lot of Vistide

En Español

On February 15, 2013, Gilead Sciences, Inc. voluntarily recalled lot B 120217A of Vistide (cidofovir injection) due to particulate matter found in some vials. Cidofovir is used to treat AIDS patients with cytomegalovirus retinitis.

Lot B 120217A was distributed in the U.S., Canada, and Europe to wholesalers and hospital and retail pharmacies.

Patients injected with particulate matter can face effects that vary depending on the amount injected, particle size, and medical condition. It should be noted that effects can be severe.

Which Tablets are Involved in the Recall?

Number B120217A is the lot being recalled. Health care providers need to check the vials before injections to insure that the vial is not from B120217A. This information can be found on the label of the product located at the side of the vials.

All other Gilead products are not affected.

What Should I Do if I have a Recalled Product?

Gilead has reached out to it’s distributors and customers to arrange for a return of all recalled product. In the U.S., to return the recalled product, call Stericycle at 1-888-965-5791, Monday through Friday from 8:00 AM to 8:00 PM Eastern Time. Patients should contact their physician if any problem relating to using Vistide is experienced.

For questions or concerns health care providers can contact Gilead Medical Information at 1-800-445-3235.